---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-099121"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:13:58.853536+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# VYNE Therapeutics reports positive Phase 1a SAD data for VYN202; no drug-related adverse events

## Summary
- VYN202 well tolerated across all dose groups; no serious or drug-related AEs, no clinically significant lab/ECG abnormalities.
- PK results showed dose-dependent exposure of VYN202 in plasma and urine across all doses tested.
- PD activity observed: increased HEXIM1 (target engagement) and inhibitory effect on inflammatory biomarkers for psoriasis and rheumatoid arthritis.
- Dosing in the multiple ascending dose (MAD) portion of Phase 1a has begun; results expected Q4 2024.
- CEO David Domzalski highlighted milestone for the company's BD2-selective BET inhibitor platform.

## SEC filing metadata
- accession: 0001104659-24-099121
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465924099121/0001104659-24-099121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465924099121/tm2423851d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-099121
- JSON: https://secwatch.observer/filing/0001104659-24-099121.json
- Plain text: https://secwatch.observer/filing/0001104659-24-099121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.